Aspirin link to CRC protection dependent on genetics, study says

Aspirin has been found to protect against colorectal cancer, but a new study suggests the ability of aspirin and related NSAIDs to prevent CRC is associated with genetic make-up, according to a Medscape report.

Advertisement

The study researchers, published in JAMA, found that aspirin or NSAIDS was associated with a lower CRC risk in the majority of the cohort, but those with a rare genotype who used aspirin had an increased risk of CRC. Four percent to 5 percent of the cohort had the rare genotype.

More articles on gastroenterology:
Dr. Carol Morris joins Bayhealth Gastroenterology
Olympus faces 5 lawsuits in wake of UCLA outbreak
Check-Cap IPO unites to trade separately from March 18 onwards

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.